Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2024 · 10-Q
Revenue$318.18M$318.18M+7.0% vs Q2 2023 Net Income$24.91M$24.91M−25.0% vs Q2 2023 EPS Diluted$0.48$0.48−25.0% vs Q2 2023 Gross Profit$170,510,000+8.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$99,124,000+13.9% Free Cash Flowderived$90,011,000+76.2% Margins · derivedGross margin53.6%+0.5 pt vs Q2 2023
Operating margin11.1%−4.6 pt vs Q2 2023
Net margin7.8%−3.3 pt vs Q2 2023
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end